BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
Financial Outlook | Analysts project trial completion by 2025, with price targets ranging from $4 to $25. Current market cap at $9.47M with negative EBITDA of $7.69M |
Market Dynamics | Explore BioCardia's position in the competitive cell therapy landscape, with promising initial results setting high expectations for cardiovascular treatment |
Regulatory Milestones | FDA protocol amendment and CMS reimbursement approval boost CardiAMP HF II trial, expanding patient eligibility and mitigating study costs |
Pivotal Trial Phase | BioCardia's CardiAMP cell therapy system enters critical Phase 3 trial, potentially revolutionizing heart failure treatment for ischemic HFrEF patients |
Metrics to compare | BCDA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBCDAPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.5x | −0.9x | −0.5x | |
PEG Ratio | −0.03 | 0.00 | 0.00 | |
Price / Book | 4.3x | 1.1x | 2.6x | |
Price / LTM Sales | 166.6x | 5.7x | 3.0x | |
Upside (Analyst Target) | - | 360.7% | 53.8% | |
Fair Value Upside | Unlock | 27.6% | 9.2% | Unlock |